Apollo Endosurgery to Present at HC Wainwright Conference

Apollo Endosurgery (NASDAQ: APEN) will present at the HC Wainwright & Co. Global Investment Conference on September 15, 2020, at 3:00 PM Eastern Time.

Rhea-AI Summary

Apollo Endosurgery (NASDAQ: APEN) will present at the HC Wainwright & Co. Global Investment Conference on September 15, 2020, at 3:00 PM Eastern Time. CEO Todd Newton and CFO Stefanie Cavanaugh will lead the presentation and hold one-on-one meetings with qualified investors. Apollo specializes in less invasive medical devices for gastrointestinal and bariatric procedures, offering alternatives to traditional surgery. Their products are available in over 75 countries, including the OverStitch™ and ORBERA® systems.

Argus Session date unavailable

+17.97% session move Open Argus

Details

News Market Reaction – APEN

The recorded move for APEN in the trading session of this news was +17.97%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

AUSTIN, TX / ACCESSWIRE / September 11, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that it will present at the HC Wainwright & Co. Global Investment Conference on Tuesday, September 15 at 3:00 PM Eastern Time. Todd Newton, CEO, and Stefanie Cavanaugh, CFO, will be presenting and available for one-on-one investor meetings.

Institutional and other qualified investors may request one-on-one meetings via HC Wainwright & Co. if they have an existing relationship, or by contacting Apollo 's investor relations, Matt Kreps of Darrow Associates, at mkreps@darrowir.com.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal complications to the treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 75 countries today and include the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.

Apollo's common stock is traded on the Nasdaq Global Market under the symbol "APEN". For more information regarding Apollo Endosurgery, go to: www.apolloendo.com.

Contacts:

Apollo Endosurgery, Inc.
Stefanie Cavanaugh, 512-279-5100
investor-relations@apolloendo.com

Darrow Associates Investor Relations
Matt Kreps, 214-597-8200
mkreps@darrowir.com

SOURCE: Apollo Endosurgery, Inc.

View source version on accesswire.com:
https://www.accesswire.com/605794/Apollo-Endosurgery-to-Present-at-HC-Wainwright-Conference

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Apollo Endosurgery present at the HC Wainwright Conference?

Apollo Endosurgery will present at the HC Wainwright & Co. Global Investment Conference on September 15, 2020.

Who will represent Apollo Endosurgery at the conference?

CEO Todd Newton and CFO Stefanie Cavanaugh will represent Apollo Endosurgery at the conference.

How can investors meet with Apollo Endosurgery management?

Qualified investors can request one-on-one meetings through HC Wainwright & Co. or by contacting Apollo's investor relations.

What is the focus of Apollo Endosurgery's products?

Apollo Endosurgery focuses on less invasive therapies for gastrointestinal conditions and obesity treatment.

What products does Apollo Endosurgery offer?

Apollo offers products like the OverStitch™ Endoscopic Suturing System and the ORBERA® Intragastric Balloon.

What is the stock symbol for Apollo Endosurgery?

Apollo Endosurgery is traded on the Nasdaq Global Market under the symbol APEN.